Caribou Biosciences

Caribou Biosciences is a clinical-stage CRISPR genome-editing biotech co-founded by Jennifer Doudna, the 2020 Nobel laureate in Chemistry for CRISPR-Cas9. The company holds the original Cas9 patent portfolio licensed from UC Berkeley and developed a proprietary chRDNA (CRISPR hybrid RNA-DNA) editing platform that produces cleaner edits than standard Cas9. The application focus is allogeneic chimeric antigen receptor T-cell (CAR-T) therapy — off-the-shelf cell therapies that compete with autologous CAR-T products like Novartis Kymriah, Gilead Yescarta and Bristol Myers Squibb Breyanzi.

Three lead candidates carry the equity value. CB-010 is an allogeneic anti-CD19 CAR-T for relapsed/refractory large B-cell lymphoma — Phase 1 ANTLER trial data show durable complete responses competitive with autologous standards. CB-011 is an allogeneic anti-BCMA CAR-T for relapsed/refractory multiple myeloma — Phase 1 CaMMouflage trial in progress. CB-012 is an allogeneic anti-CLL-1 CAR-T for acute myeloid leukemia — early clinical with binary readouts ahead. The science is real and the platform is patent-protected; the question is whether commercial-stage allogeneic CAR-T ever happens.

Financials are pre-revenue biotech reality. Revenue 11.2 million USD trailing (collaboration milestones, not product sales). Operating margin -1,096 percent — the company burns 60 million USD per year of free cash flow against minimal revenue. Current ratio 6.22 (cash position approximately 200 million USD) gives roughly three years of runway before a financing event. Market cap 212 million USD, 97 employees, headquartered in Berkeley, California. Forward P/E -1.53 confirms continued losses through 2026.

13F filings show specialist biotech-fund concentration — RA Capital, Avoro Capital, Perceptive and Baker Brothers all hold positions. The strong_buy analyst consensus (7 analysts) with target mean 12.00 USD against a 2.14 USD share price is one of the most extreme upside calls in the entire small-cap biotech universe — but the spread (target high 32.00 USD, target low 4.00 USD) signals analyst disagreement on binary clinical outcomes. Short interest 7.48 percent (short ratio 4.9 days) is moderate; insiders have not been net sellers despite the decline.

EV/Revenue 10.85 and EV/EBITDA -1.06 are meaningless for a clinical-stage biotech. P/B 2.03 reflects cash plus IP value. Sum-of-parts: cash position roughly 200 million USD; CB-010 risk-adjusted NPV roughly 300 million USD at 30 percent probability of approval and peak sales of 1 billion USD; CB-011 and CB-012 each add option value of 50-100 million USD; IP portfolio adds 100-200 million USD. Fair-value range 650 million to 900 million USD versus current 212 million USD market cap — 3-4x upside aligned with analyst mean target. Analyst high 32.00 USD prices CB-010 plus CB-011 both succeeding. Analyst low 4.00 USD prices cash plus IP only. The 460 percent upside is real but probability-weighted, not expected.

1. :
2. :
3. :

Caribou is a binary speculative biotech with real science and a defensible patent estate. The asymmetric analyst target of 12.00 USD against 2.14 USD reflects an option-like payoff. Position size should be 0.5-1 percent of portfolio with full awareness that a Phase 2 miss takes the stock to 1 USD or below. The Doudna connection is marketing, not a moat — the platform stands on its own clinical data. Buy only if you have meaningful position diversification across 6-10 such speculative biotechs; never as a concentrated position. CB-010 ANTLER pivotal readout is the catalyst that decides outcome.